Core Viewpoint - The stock of Pagoda Biopharma-B (02565) surged over 20% following the announcement of a strategic partnership with UAE-based PDC FZ-LLC for the development and commercialization of its core product, Visepegenatide (PB-119), in the Middle East and Africa [1] Company Summary - Pagoda Biopharma's stock reached a new high of 62.25 HKD, with a current trading price of 60.3 HKD and a trading volume of 30.23 million HKD [1] - The strategic partnership with PDC FZ-LLC marks a significant step in Pagoda Biopharma's global commercialization strategy [1] Product Summary - Visepegenatide (PB-119) is a GLP-1 receptor agonist developed by Pagoda Biopharma, designed for weekly subcutaneous injection to treat type 2 diabetes and assist in weight management [1] - The prevalence of diabetes in the Middle East and North Africa is notably high, with a rate of 16.2% among adults, the highest globally, indicating a substantial market opportunity for Visepegenatide [1]
港股异动 | 派格生物医药-B(02565)尾盘涨超20%再创新高 近期授出糖尿病药物于中东及非洲独家许可